Key result
Osimertinib triggers Takotsubo cardiomyopathy with recurrence upon half-dose rechallenge.
Why the study?
Osimertinib has been reported to cause heart failure, but Takotsubo cardiomyopathy induced by osimertinib had not been previously reported in detail.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
A patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib. Reoccurrence of TC was seen after readministrating half dose of osimertinib.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (2022) conducted a case report in Non-small-cell lung cancer and Takotsubo cardiomyopathy (n=1). Osimertinib was evaluated. A 73-year-old woman developed symptomatic heart failure due to Takotsubo cardiomyopathy after taking osimertinib, with asymptomatic reoccurrence observed upon readministration at half the dose.
Synapse has enriched 10 related papers. Consider them for comparative context: